Institution
Tata Memorial Hospital
Healthcare•Mumbai, India•
About: Tata Memorial Hospital is a healthcare organization based out in Mumbai, India. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 3187 authors who have published 4636 publications receiving 109143 citations.
Topics: Cancer, Breast cancer, Population, Radiation therapy, Carcinoma
Papers published on a yearly basis
Papers
More filters
••
University of Amsterdam1, University of Verona2, University of Milan3, Karolinska University Hospital4, Mayo Clinic5, Heidelberg University6, Trinity College, Dublin7, University of Barcelona8, National and Kapodistrian University of Athens9, Medical University of Graz10, Technische Universität München11, Harvard University12, University of Belgrade13, University of Liverpool14, Tata Memorial Hospital15, University of Pennsylvania16, Thomas Jefferson University17, Freeman Hospital18
TL;DR: Standard lymphadenectomy for pancreatoduodenectomy should strive to resect Ln stations no. 5, 6, 8a, 12b1,12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b, for cancers of the body and tail of the pancreas, removal of stations 10, 11, and 18 is standard.
484 citations
••
Virginia Mason Medical Center1, University of Birmingham2, University of São Paulo3, University of Michigan4, Toronto General Hospital5, St Thomas' Hospital6, Aix-Marseille University7, University of Amsterdam8, University of Texas MD Anderson Cancer Center9, Keio University10, Queen Mary University of London11, Harvard University12, Katholieke Universiteit Leuven13, Tata Memorial Hospital14, University Hospitals Birmingham NHS Foundation Trust15, Trinity College, Dublin16, University of Cologne17, University of Queensland18, Erasmus University Rotterdam19
TL;DR: Standardized methods provide contemporary international benchmarks for reporting outcomes after esophagectomy, using a standardized dataset with specific definitions to prospectively collect international data to provide a benchmark for complications and outcomes associated with esphagectomy.
Abstract: Objective:Utilizing a standardized dataset with specific definitions to prospectively collect international data to provide a benchmark for complications and outcomes associated with esophagectomy.Summary of Background Data:Outcome reporting in oncologic surgery has suffered from the lack of a stand
453 citations
••
Medical University of Vienna1, Aarhus University Hospital2, University Medical Center Utrecht3, Leiden University Medical Center4, University of Cambridge5, Institut Gustave Roussy6, Tata Memorial Hospital7, Oslo University Hospital8, Post Graduate Institute of Medical Education and Research9, University of Alberta10, Katholieke Universiteit Leuven11, Université de Montréal12, Netherlands Cancer Institute13
TL;DR: The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state-of-the-art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachyTherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced external beam radiotherapy (EBRT) and IC/IS) techniques.
413 citations
••
TL;DR: The efficacy and safety of panitumumab combined with cisplatin and fluorouracil as first-line treatment for patients with recurrent or metastatic squamous-cell carcinoma of the head and neck and tumour human papillomavirus (HPV) status as a potential predictive biomarker of outcomes were assessed.
Abstract: Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN). We assessed the efficacy and safety of panitumumab combined with cisplatin and fluorouracil as first-line treatment for these patients. Methods This open-label phase 3 randomised trial was done at 126 sites in 26 countries. Eligible patients were aged at least 18 years; had histologically or cytologically confirmed SCCHN; had distant metastatic or locoregionally recurrent disease, or both, that was deemed to be incurable by surgery or radiotherapy; had an Eastern Cooperative Oncology Group performance status of 1 or less; and had adequate haematological, renal, hepatic, and cardiac function. Patients were randomly assigned according to a computer-generated randomisation sequence (1:1; stratified by previous treatment, primary tumour site, and performance status) to one of two groups. Patients in both groups received up to six 3-week cycles of intravenous cisplatin (100 mg/m 2 on day 1 of each cycle) and fluorouracil (1000 mg/m 2 on days 1–4 of each cycle); those in the experimental group also received intravenous panitumumab (9 mg/kg on day 1 of each cycle). Patients in the experimental group could choose to continue maintenance panitumumab every 3 weeks. The primary endpoint was overall survival and was analysed by intention to treat. In a prospectively defined retrospective analysis, we assessed tumour human papillomavirus (HPV) status as a potential predictive biomarker of outcomes with a validated p16-INK4A (henceforth, p16) immunohistochemical assay. Patients and investigators were aware of group assignment; study statisticians were masked until primary analysis; and the central laboratory assessing p16 status was masked to identification of patients and treatment. This trial is registered with ClinicalTrials.gov, number NCT00460265. Findings Between May 15, 2007, and March 10, 2009, we randomly assigned 657 patients: 327 to the panitumumab group and 330 to the control group. Median overall survival was 11·1 months (95% CI 9·8–12·2) in the panitumumab group and 9·0 months (8·1–11·2) in the control group (hazard ratio [HR] 0·873, 95% CI 0·729–1·046; p=0·1403). Median progression-free survival was 5·8 months (95% CI 5·6–6·6) in the panitumumab group and 4·6 months (4·1–5·4) in the control group (HR 0·780, 95% CI 0·659–0·922; p=0·0036). Several grade 3 or 4 adverse events were more frequent in the panitumumab group than in the control group: skin or eye toxicity (62 [19%] of 325 included in safety analyses vs six [2%] of 325), diarrhoea (15 [5%] vs four [1%]), hypomagnesaemia (40 [12%] vs 12 [4%]), hypokalaemia (33 [10%] vs 23 [7%]), and dehydration (16 [5%] vs seven [2%]). Treatment-related deaths occurred in 14 patients (4%) in the panitumumab group and eight (2%) in the control group. Five (2%) of the fatal adverse events in the panitumumab group were attributed to the experimental agent. We had appropriate samples to assess p16 status for 443 (67%) patients, of whom 99 (22%) were p16 positive. Median overall survival in patients with p16-negative tumours was longer in the panitumumab group than in the control group (11·7 months [95% CI 9·7–13·7] vs 8·6 months [6·9–11·1]; HR 0·73 [95% CI 0·58–0·93]; p=0·0115), but this difference was not shown for p16-positive patients (11·0 months [7·3–12·9] vs 12·6 months [7·7–17·4]; 1·00 [0·62–1·61]; p=0·998). In the control group, p16-positive patients had numerically, but not statistically, longer overall survival than did p16-negative patients (HR 0·70 [95% CI 0·47–1·04]). Interpretation Although the addition of panitumumab to chemotherapy did not improve overall survival in an unselected population of patients with recurrent or metastatic SCCHN, it improved progression-free survival and had an acceptable toxicity profile. p16 status could be a prognostic and predictive marker in patients treated with panitumumab and chemotherapy. Prospective assessment will be necessary to validate our biomarker findings. Funding Amgen Inc.
401 citations
••
TL;DR: RapidArc was investigated for cervix uteri cancer showing significant improvements in organs at risk and healthy tissue sparing with uncompromised target coverage leading to better conformal avoidance of treatments w.r.t. IMRT.
393 citations
Authors
Showing all 3213 results
Name | H-index | Papers | Citations |
---|---|---|---|
Al B. Benson | 113 | 578 | 48364 |
Keitaro Matsuo | 97 | 818 | 37349 |
Ashish K. Jha | 87 | 503 | 30020 |
Noopur Raje | 82 | 506 | 27878 |
Muthupandian Ashokkumar | 76 | 511 | 20771 |
Snehal G. Patel | 73 | 367 | 16905 |
Rainu Kaushal | 58 | 232 | 16794 |
Ajit S. Puri | 54 | 369 | 9948 |
Jasbir S. Arora | 51 | 351 | 15696 |
Sudeep Sarkar | 48 | 273 | 10087 |
Ian T. Magrath | 47 | 107 | 8084 |
Pankaj Chaturvedi | 45 | 325 | 15871 |
Pradeep Kumar Gupta | 44 | 416 | 7181 |
Shiv K. Gupta | 43 | 150 | 8911 |
Kikkeri N. Naresh | 43 | 245 | 6264 |